

Ulrike Leiter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6232951/publications.pdf>

Version: 2024-02-01

127
papers

7,513
citations

57758

44
h-index

62596

80
g-index

150
all docs

150
docs citations

150
times ranked

7757
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical determinants of long-term survival in metastatic uveal melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1467-1477.	4.2	10
2	S1â€ guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 235-243.	0.8	8
3	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. <i>Cancers</i> , 2022, 14, 518.	3.7	6
4	Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS. <i>Acta Dermato-Venereologica</i> , 2022, , .	1.3	0
5	Genetic characterization of advanced conjunctival melanoma and response to systemic treatment. <i>European Journal of Cancer</i> , 2022, 166, 60-72.	2.8	7
6	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	1.6	33
7	What causes the death of patients with cutaneous squamous cell carcinoma? A prospective analysis in 1400 patients. <i>European Journal of Cancer</i> , 2022, 172, 182-190.	2.8	4
8	Immun-Checkpoint-Blockade bei fortgeschrittenem kutanen Plattenepithelkarzinom: Was wissen wir derzeit im Jahr 2020?. <i>Karger Kompass Dermatologie</i> , 2021, 9, 114-128.	0.0	0
9	Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. <i>Targeted Oncology</i> , 2021, 16, 197-205.	3.6	12
10	Online consensus conferences for the development and update of clinical practice guidelines: A survey among participants of the German S3 guideline on actinic keratosis and cutaneous squamous cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 608-610.	0.8	3
11	What is new in the 2020 British guidelines for cutaneous squamous cell carcinoma?. <i>British Journal of Dermatology</i> , 2021, 184, 384-385.	1.5	0
12	Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3313-3322.	4.2	17
13	Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under realâ€ world conditions in Germany â€ The nonâ€ interventional study NIELS. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1678-1685.	2.4	10
14	Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943â€2036. <i>European Journal of Cancer</i> , 2021, 152, 18-25.	2.8	49
15	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. <i>Cancers</i> , 2021, 13, 3359.	3.7	18
16	Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis. <i>JAMA Dermatology</i> , 2021, 157, 1066.	4.1	24
17	Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. <i>European Journal of Cancer</i> , 2021, 159, 98-104.	2.8	11
18	Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany. <i>Acta Dermato-Venereologica</i> , 2021, 102, adv00637.	1.3	3

#	ARTICLE	IF	CITATIONS
19	Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. <i>Cancers</i> , 2021, 13, 6141.	3.7	11
20	Late recurrence of melanoma after 10 years – Is the course of the disease different from early recurrences?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 977-983.	2.4	4
21	Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. , 2020, 8, e000897.		40
22	Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. <i>European Journal of Cancer</i> , 2020, 138, 125-132.	2.8	44
23	A Systematic Review and Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing Surveillance Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 2253.	2.4	11
24	The evolving field of Dermatocarcinology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV – UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2183-2197.	2.4	22
25	Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9300.	4.1	23
26	Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 1438.	2.4	11
27	The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node – positive melanoma without the need for completion lymph node dissection. <i>European Journal of Cancer</i> , 2020, 134, 9-18.	2.8	11
28	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , 2020, 38, 2543-2551.	1.6	40
29	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality – care indicators. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 275-294.	0.8	57
30	Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2021-2025.	2.4	16
31	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) – short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 400-413.	0.8	39
32	Primary Resistance to PD-1-Based Immunotherapy – A Study in 319 Patients with Stage IV Melanoma. <i>Cancers</i> , 2020, 12, 1027.	3.7	17
33	Epidemiology of Skin Cancer: Update 2019. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1268, 123-139.	1.6	184
34	Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. <i>European Journal of Cancer</i> , 2019, 123, 83-91.	2.8	15
35	Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 44-51.	2.4	34
36	Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 999-1004.	0.8	7

#	ARTICLE	IF	CITATIONS
37	Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. <i>Journal of Clinical Oncology</i> , 2019, 37, 3000-3008.	1.6	155
38	Kein Überlebensvorteil beim Sentinel-Lymphknoten-positiven Melanom mit sofortiger kompletter Lymphadenektomie – eine Übersicht. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 7-14.	0.8	0
39	Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1299-1307.e7.	1.2	8
40	Time trends in incidence and mortality of cutaneous melanoma in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1272-1280.	2.4	49
41	Lack of survival benefit in sentinel lymph node-positive melanoma with immediate complete lymphadenectomy – a review. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 7-13.	0.8	11
42	Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns – Results of a non-interventional study of the DeCOG. <i>European Journal of Cancer</i> , 2018, 96, 34-43.	2.8	97
43	Pediatric patients with cutaneous melanoma: A European study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26974.	1.5	26
44	Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. <i>British Journal of Dermatology</i> , 2018, 178, 443-451.	1.5	78
45	Lymph node dissection for melanoma using tumescence local anaesthesia: an observational study. <i>European Journal of Dermatology</i> , 2018, 28, 177-185.	0.6	17
46	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. <i>British Journal of Cancer</i> , 2018, 119, 339-346.	6.4	83
47	Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 703-708.	2.5	4
48	Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1860-1867.	0.7	149
49	Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP). <i>Klinische Padiatrie</i> , 2017, 229, 322-328.	0.6	16
50	Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 517-532.	5.7	41
51	Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2570-2577.	0.7	24
52	Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2309-2315.	0.7	124
53	Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 757-767.	10.7	562
54	Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy. <i>European Journal of Cancer</i> , 2016, 67, 38-45.	2.8	10

#	ARTICLE	IF	CITATIONS
55	Melanoma burden by melanoma stage: Assessment through a disease transition model. <i>European Journal of Cancer</i> , 2016, 53, 33-41.	2.8	20
56	Increased CCL17 serum levels are associated with improved survival in advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1075-1082.	4.2	16
57	Current diagnosis and treatment of basal cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 863-875.	0.8	45
58	443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011. <i>European Journal of Cancer</i> , 2015, 51, 861-868.	2.8	45
59	Sentinel Lymph Node Dissection in Head and Neck Melanoma has Prognostic Impact on Disease-Free and Overall Survival. <i>Annals of Surgical Oncology</i> , 2015, 22, 4073-4080.	1.5	28
60	Screening for skin cancer in bank and insurance employees: risk profile and correlation of self and physician's assessment. <i>International Journal of Dermatology</i> , 2015, 54, 419-423.	1.0	0
61	Ultraviolet exposure and risk of melanoma and basal cell carcinoma in Ulm and Dresden, Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 134-142.	2.4	30
62	BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy. <i>PLoS ONE</i> , 2014, 9, e89218.	2.5	18
63	<i>Epidemiology of Skin Cancer.</i> , 2014, 810, 120-140.		406
64	Local recurrence and survival in acral lentiginous melanoma comparing 3D histology and conventional histology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 881-889.	0.8	2
65	Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. <i>Melanoma Research</i> , 2014, 24, 512-516.	1.2	40
66	Follow-up in patients with low-risk cutaneous melanoma: is it worth it?. <i>Melanoma Management</i> , 2014, 1, 115-125.	0.5	2
67	Proliferative Activity, Chromosomal Aberrations, and Tumor-Specific Mutations in the Differential Diagnosis between Blue Nevi and Melanoma. <i>American Journal of Pathology</i> , 2013, 182, 640-645.	3.8	33
68	Effective Combination of Photodynamic Therapy and Imiquimod 5% Cream in the Treatment of Actinic Keratoses: Three Cases. <i>BioMed Research International</i> , 2013, 2013, 1-5.	1.9	10
69	Targeting hyperactivation of the <sc>AKT</sc> survival pathway to overcome therapy resistance of melanoma brain metastases. <i>Cancer Medicine</i> , 2013, 2, 76-85.	2.8	126
70	Malignes Melanom S3-Leitlinie – Diagnostik, Therapie und Nachsorge des Melanoms. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 1-126.	0.8	9
71	Malignant Melanoma S3-Guideline – Diagnosis, Therapy and Follow-up of Melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 1-116.	0.8	122
72	S3-Guideline – Diagnosis, therapy and follow-up of melanoma – short version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 563-602.	0.8	63

#	ARTICLE	IF	CITATIONS
73	Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis. PLoS ONE, 2013, 8, e63137.	2.5	26
74	Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour. PLoS ONE, 2013, 8, e66953.	2.5	22
75	Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy. PLoS ONE, 2013, 8, e81624.	2.5	54
76	Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. British Journal of Cancer, 2012, 107, 422-428.	6.4	129
77	Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry. Journal of the American Academy of Dermatology, 2012, 66, 37-45.	1.2	84
78	Recurrent nodules in a periauricular plaque-type blue nevus with fatal outcome. Journal of Cutaneous Pathology, 2012, 39, 1088-1093.	1.3	29
79	Skin cancer in organ transplant recipients. Expert Review of Dermatology, 2012, 7, 37-45.	0.3	1
80	Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma. PLoS ONE, 2012, 7, e29791.	2.5	14
81	Open label randomized study comparing 3-month vs. 6-month treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 48-53.	2.4	52
82	Sex differences in survival of cutaneous melanoma are age dependent. Melanoma Research, 2011, 21, 244-252.	1.2	36
83	Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009. Melanoma Research, 2011, 21, 228-234.	1.2	29
84	Extramammary Paget's Disease: Extended Subclinical Growth Detected Using Three-Dimensional Histology in Routine Paraffin Procedure and Course of the Disease. Dermatologic Surgery, 2011, 37, 1417-1426.	0.8	19
85	In Reply: Sentinel Lymph Node Biopsy in Melanoma. Annals of Surgical Oncology, 2011, 18, 598-599.	1.5	2
86	Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunology, Immunotherapy, 2011, 60, 487-493.	4.2	51
87	Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma. PLoS ONE, 2011, 6, e16882.	2.5	22
88	Sentinel Lymph Node Dissection in Primary Melanoma Reduces Subsequent Regional Lymph Node Metastasis as Well as Distant Metastasis After Nodal Involvement. Annals of Surgical Oncology, 2010, 17, 129-137.	1.5	45
89	Determinants of survival in patients with brain metastases from cutaneous melanoma. British Journal of Cancer, 2010, 102, 1213-1218.	6.4	147
90	Melanoma staging: Facts and controversies. Clinics in Dermatology, 2010, 28, 275-280.	1.6	21

#	ARTICLE	IF	CITATIONS
91	Incisional biopsy and melanoma prognosis: Facts and controversies. Clinics in Dermatology, 2010, 28, 316-318.	1.6	83
92	Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies. Clinics in Dermatology, 2010, 28, 311-315.	1.6	23
93	Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?. Melanoma Research, 2010, 20, 240-246.	1.2	46
94	Clinical course and prognostic factors of Merkel cell carcinoma of the skin. British Journal of Dermatology, 2009, 161, 90-94.	1.5	36
95	Melanoma epidemiology and trends. Clinics in Dermatology, 2009, 27, 3-9.	1.6	556
96	Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. Journal of the American Academy of Dermatology, 2009, 60, 863-868.	1.2	18
97	Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. Melanoma Research, 2009, 19, 50-57.	1.2	50
98	Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer, 2008, 112, 1795-1804.	4.1	211
99	Epidemiology of Melanoma and Nonmelanoma Skin Cancer – The Role of Sunlight. Advances in Experimental Medicine and Biology, 2008, 624, 89-103.	1.6	582
100	Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Annals of Oncology, 2008, 19, 801-806.	1.2	27
101	Management of primary and metastasized melanoma in Germany in the time period 1976 – 2005: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Melanoma Research, 2008, 18, 112-119.	1.2	4
102	Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976 – 2001. Cancer, 2007, 109, 1174-1182.	4.1	47
103	Comparative analysis of incidence and clinical features of cutaneous malignant melanoma in Crete (Greece) and southern Germany (central Baden-Württemberg). British Journal of Dermatology, 2006, 154, 1123-1127.	1.5	16
104	Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. British Journal of Dermatology, 2006, 155, 771-777.	1.5	98
105	The incidence and mortality of cutaneous melanoma in southern Germany. Cancer, 2006, 107, 1331-1339.	4.1	119
106	Development of prognostic factors and survival in cutaneous melanoma over 25 years. Cancer, 2005, 103, 616-624.	4.1	93
107	Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group. Journal of Clinical Oncology, 2005, 23, 9001-9007.	1.6	111
108	Numerical abnormalities of the Cyclin D1 gene locus on chromosome 11q13 in non-melanoma skin cancer. Cancer Letters, 2005, 219, 197-204.	7.2	16

#	ARTICLE	IF	CITATIONS
109	Prognostic Factors of Thin Cutaneous Melanoma: An Analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. <i>Journal of Clinical Oncology</i> , 2004, 22, 3660-3667.	1.6	112
110	Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry. <i>Journal of Clinical Oncology</i> , 2004, 22, 4376-4383.	1.6	52
111	The natural course of cutaneous melanoma. <i>Journal of Surgical Oncology</i> , 2004, 86, 172-178.	1.7	215
112	Diagnostic value and prognostic significance of protein Sâ€100Î², melanomaâ€inhibitory activity, and tyrosinase/MARTâ€1 reverse transcriptionâ€polymerase chain reaction in the followâ€up of highâ€risk melanoma patients. <i>Cancer</i> , 2003, 97, 1737-1745.	4.1	115
113	Chronic cutaneous sclerodermoid graft-versus-host disease: evaluation by 20-MHz sonography. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003, 17, 402-407.	2.4	32
114	Expression of c-myc and bcl-2 in Primary and Advanced Cutaneous Melanoma. <i>Cancer Investigation</i> , 2002, 20, 914-921.	1.3	25
115	Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2002, 18, 183-190.	1.5	42
116	The PUVA-turban as a new option of applying a dilute psoralen solution selectively to the scalp of patients with alopecia areata. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 248-252.	1.2	44
117	Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. <i>European Journal of Cancer</i> , 2001, 37, 251-259.	2.8	84
118	UVB-induced Decrease of p16/CDKN2A Expression in Skin Cancer Patients. <i>Pigment Cell & Melanoma Research</i> , 2001, 14, 201-205.	3.6	5
119	Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. <i>British Journal of Cancer</i> , 2001, 84, 72-79.	6.4	114
120	S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. <i>Anticancer Research</i> , 2001, 21, 1311-6.	1.1	62
121	Quantitation of Herpes simplex DNA in Blood during Aciclovir Therapy with Competitive PCR ELISA. <i>Dermatology</i> , 2000, 201, 296-299.	2.1	8
122	PUVA-bath photochemotherapy for congenital palmoplantar keratoderma in an 11-year-old girl. <i>British Journal of Dermatology</i> , 2000, 143, 464-465.	1.5	3
123	Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. <i>Archives of Dermatological Research</i> , 2000, 292, 225-232.	1.9	136
124	The time course of phototoxicity of topical PUVA: 8-methoxypsoralen cream-PUVA vs. 8-methoxypsoralen gel-PUVA. <i>British Journal of Dermatology</i> , 1999, 140, 988-990.	1.5	24
125	Mycophenolate mofetil: A new therapeutic option in the treatment of blistering autoimmune diseases. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, 957-960.	1.2	99
126	Treatment of Pemphigus Vulgaris and Bullous Pemphigoid With Mycophenolate Mofetil Monotherapy. <i>Archives of Dermatology</i> , 1999, 135, 724-725.	1.4	46

#	ARTICLE	IF	CITATIONS
127	Treatment of Psoriasis With Calcipotriene Plus Psoralen-UV-A-Bath Therapy. Archives of Dermatology, 1999, 135, 861-862.	1.4	10